Introduction
The EML4 gene and the ALK gene rearrangements occur in 2%-7% of patients with non-small-cell lung cancer (NSCLC) overall. 1 Crizotinib has already shown an impressive single-agent activity in ALK-positive lung adenocarcinomas (ADCs). In ADCs, an objective response rate to crizotinib is about 60% and its median progressionfree survival is nearly 10 months. 2 However, it is known that many cases ultimately acquired resistance to crizotinib. 3 Several second-generation ALK inhibitors have been developed and are currently under evaluation in clinical trials. They have been shown to be effective for crizotinib-resistant patients, with response rates of 55% and 56%. 4, 5 Nowadays, a case of primary resistance is rare, thus the mechanisms of primary resistance to ALK inhibitors for these patients are not well-known. In this report, we present a case of successful treatment of an ALK rearrangement ADC patient transformed to epidermal growth factor receptor (EGFR) mutation with icotinib. Icotinib is a kind of EGFR-tyrosine kinase inhibitor (EGFR-TKI) that has shown effectiveness as therapy for advanced NSCLC with EGFR activating mutations, such as erlotinib and gefitinib. 6 In a Phase IV study of icotinib, it illustrated a favorable toxicity profile and efficacy in EGFR-mutated patients. 
Case report
A 49-year-old female, who was a nonsmoker, presented to our hospital with 1 month history of cough. She provided informed verbal consent to participate in this study and this study was also approved by the Institutional Review Board of Zhejiang Cancer Hospital. Figure 3G-I) . The response was considered as partial response. During treatment with icotinib, the abnormal hepatic and renal function after administration were not found. There were no treatment-related adverse events 
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Wang et al including gastrointestinal reaction, and rash. So far, after 2 months, the disease is still stable.
Discussion
NSCLCs with ALK rearrangement are highly sensitive to the ALK kinase inhibitor crizotinib. 8 Unfortunately, cases of resistance to crizotinib soon appear in NSCLC patients. Acquired resistance mechanisms to crizotinib with ALK rearranged in NSCLC have been described. 9, 10 The mechanisms of acquired resistance to ALK inhibitors can be divided into two types: ALK dominant or ALK nondominant. ALK dominant resistance mechanisms include secondary mutations and copy number gain in the ALK gene; ALK nondominant resistance mechanisms include the activation of bypass tracks, such as EGFR, KRAS, KIT, MET, and IGF-1R. 11 Doebele et al 12 reported a patient with ALK rearrangement was detected EGFR exon 21 mutation after 61 days on crizotinib. To date, there is a lack of reports to demonstrate the mechanisms of primary resistance to crizotinib with ALK-positive ADC. In our report, we experienced a rare case. Because of insufficient samples, we did not detect the initial biopsy tissue by NGS. On the other hand, the ARMS assay is sensitive, routinely being able to detect at least 1%; 13 the NGS method used appears not to be as sensitive as the real-time polymerase chain reaction methods.
14 So, we thought the initial EGFR gene testing result would not be a false negative. After resistance to crizotinib, we suggested the patient to take a re-biopsy, but she did not want to do it. Thereby, because the patient didn't want to do a re-biopsy, it is a way to use plasma to detect if other mutations will be found by NGS. Thanks to the NGS having a higher coverage, it would become a tool to overcome the tumor heterogeneity. In reality, in some cases, re-biopsy may be too difficult to be obtained. In our report, we used NGS of the plasma to detect mutation. This is a limitation in this study. Pekar-Zlotin et al 15 compared FISH, IHC, and NGS for detection of EML4-ALK rearrangement by tumor tissues in lung cancer; the sensitivity and specificity of NGS were 42.9% and 97.7%, respectively, for FISH and 100% and 97.7%, respectively, for IHC. So, the NGS assay to detect EML4-ALK rearrangement from plasma is lacking in much of the clinical research and data. To date, molecular tests in advanced NSCLC patients can be performed in different biological samples, such as transbronchial biopsy, bronchial lavage, pleural fluid, and blood. Because of the difficultly of re-biopsy, it may be a promising way to detect a gene mutation in the blood. In our report, the patient was tested for the EGFR mutation and she had a response for treatment of icotinib.
In summary, our case is the first report to demonstrate a patient harboring EGFR mutation by NGS detection after primary resistance to crizotinib and response to EGFR-TKI treatment.
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